Skip to Main Content

On April 22, 2024, UnitedHealth Group issued a press release, providing an update on the Change Healthcare cybersecurity incident that occurred on Feb. 21, 2024. Given the size of the data impacted, the investigation to determine whose data is impacted is expected to take several months. UnitedHealth Group believes this situation will impact “a substantial proportion of people in America” and is offering immediate credit monitoring and identity protection services, as well as a dedicated contact center to address questions. Visit Change Healthcare Cyberattack Support and/or reach out to the contact center at 1-866-262-5342 regarding any questions.

Long-Acting Injectables

Created by our Medical Director and Director of Pharmacy, this pre-recorded presentation is intended for prescribers. This training event will help prescribers understand how antipsychotic medication adherence decreases relapse, readmissions and hospitalization.

Learning Objectives

  • Identify the different types of medications used to treat schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, and other psychotic disorders.
  • Understand common antipsychotic side effects, the importance of routine monitoring, and the program improvement project for diabetes screening.
  • Identify barriers that may prevent members from taking long acting injectable antipsychotic (LAIA) medications.
  • Utilize clinical insights to ensure members at greatest risk for readmission and relapse are initiated on an LAIA prior to discharge

This pre-recorded training is approximately 45 minutes in length. If you have any questions, please submit them to our Pharmacy mailbox prior to the event.
Note: This course is NOT eligible for continuing education credits for any licenses.

Register to access the on-demand training, Long-Acting Injectables: Preventing Readmissions.